

Bacteriological Aspects of Late Pneumonia in Ventilated Patient in Intensive Care Units: A Single Center Study in Morocco

Frikh Mohammed^{1,2*}, Abdelhay Lemnouer^{1,2}, Nabil Alem¹, Adil Maleb³ and Mostafa Elouennass^{1,2}

¹Department of Bacteriology, Faculty of Medicine and Pharmacy, Military Hospital of Instruction Mohammed V, University Mohammed V, Rabat, Morocco

²Group of Research and Study for Antibiotic Resistance and Bacterial Infections, University Mohammed V Rabat, Morocco

³Faculty of Medicine Oujda, University Mohammed First, Morocco

*Corresponding author: Frikh Mohammed, Department of Bacteriology, Military Hospital of Instruction Mohammed V, University Mohammed V, Avenue des FAR, Hay Riad, 10100, Rabat, Morocco, Tel: +212-6 62721196; E-mail: frikmed@yahoo.fr

Received date: April 03, 2017; Accepted date: May 12, 2017; Published date: May 15, 2017

Copyright: © 2017 Mohammed F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: The resistance to antimicrobial among patients with late Ventilator-associated pneumonia (VAP) has become increasingly more common in many ICUs in Morocco. There are scarce studies assessing VAP importance in Morocco.

The aim of this study is to determine the bacterial ecology and resistance profile of late VAP in intensive care units in an academic hospital of Rabat.

Methods: A total of 215 sputum samples were collected from endotracheal aspirate in patients with diagnosis of late VAP during the study period, defined from April 1st 2012 to April 2013. The bacteriology interpretations was done following the Referential of Medical Microbiology (REMIC 2010) and were quantitatively cultured with a cut-off of ≥ 10 UFC/ml for endotracheal aspiration samples.

Results: Overall, the Gram-negative bacilli (GNB) represent 81.42% of isolates, while Gram-positive was less represented with a rate of 18.56%. Non-lactose fermenting GNB made up the half of pathogens with the rate of 55.23% and the prevalence of Enteric GNB reaches 26.19%. *Pseudomonas aeruginosa* is the most isolates with the rate of 28.57%, followed by *Acinetobacter baumannii* (24.76%), *Staphylococcus aureus* (9.5%) and *Klebsiella pneumonia* (8.09%). A high level of multi-drug resistance pathogens was found with a rate of 39.52%. They included *Pseudomonas aeruginosa* (14.28%), *Acinetobacter baumannii* (19.04%) and *Klebsiella pneumonia* (5.71%) whereas all *S. aureus* were methicillin-sensitive.

Conclusion: The local bacterial pathogens isolates displayed high levels of antibiotic resistance. Enteric GNB naturally resistant to Polymyxin E and *Corynebacterium* species are likely to be emerging pathogens. This study significantly highlights the need to take into account these potentially drug-resistant isolates when making empiric antibiotic treatment.

Keywords: Ventilator-associated pneumonia (VAP); Antimicrobial resistance; Nosocomial infections

Background

Ventilator-associated pneumonia (VAP) is a very common type of infection in intensive care unit (ICU) patients [1]. Late onset VAP is defined as VAP developing ≥ 5 days of mechanical ventilation. It is caused by multidrug-resistant (MDR) pathogens, and is associated with increased morbidity and mortality [2,3].

VAP could be considered a form of aspiration (gravity) pneumonia in intubated patients. Indeed, pooled secretions present in the subglottic area above inflated endotracheal tube cuff may be aspirated into the lower airways [4]. The international nosocomial infection control consortium (INICC) data suggests a VAP incidence as high as 13.6/1000 mechanical ventilation (MV) days [1]. In developing countries, the rates of VAP infections varied from 10 to 41.7/1000 MV-days, and were generally higher than NHSN benchmark rates [5].

In Morocco, the incidence of VAP in a tertiary medical ICU of Rabat was 43.2 per 1,000 ventilator-days [6] and the prevalence was found to be 71.4 % to 93% [7,8].

VAP are associated with mortality rates ranging between 20% and 70% that can be even more important when VAP are caused by multiple drug-resistant pathogens or when the first antibiotic is inadequate [9-11]. It is also linked with extended ICU and hospital stay, delay in recovery, and augmented health care expenses [12-14].

Many studies investigated the risk factors for VAP infections and found that the male sex, elderly age, higher APACHE II scores, prolonged antibiotic usage, immunosuppression, reintubation, etc... are the most common ones [15].

Because of the grave consequences of VAP, its prevention has gained the attention of policy makers for developing patients' safety plans [9,16].

The Institute for Healthcare Improvement (IHI) [17,18] has promoted VAP prevention and safety of patients on mechanical

ventilation by implementing a set of interventions known as the 'ventilator bundle' [19]. This bundle includes four components: (1) elevation of the head of the bed to between 30 and 45 degrees, (2) daily interruption of sedation and daily assessment of readiness to extubate, (3) peptic ulcer disease prophylaxis, and (4) deep vein thrombosis prophylaxis. Others reports added to these approaches: staff education programs and implementation of hand hygiene [5] and showed that the VAP rate can be reduced significantly by applying these preventive measures [20-23].

The VAP causative agents varies according to the population of patients in the ICU, the durations of hospital and ICU stays, and the specific diagnostic method(s) used [5,24-28]. *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Enterobacteriaceae* producing extended-spectrum beta-lactamase (ESBL) and methicillin-resistant *Staphylococcus aureus* (MRSA) are the species most frequently isolated [24,29,30]. In developing countries, Gram-negative bacilli were responsible for the majority of VAP episodes (41-92%) followed by Gram-positive cocci (6-58%) [31-35].

In Morocco, most studies reported the ecology of VAP including both early and late ones (the latter representing 55 to 66% of cases). Bacteriological profile in these studies was dominated by BGN (48,3-68,3%), *Staphylococcus* (21,2-5,5%) and *Enterobacteriaceae* (10,7-15%) with predominance of multidrug resistance especially for BGN [36,37].

The aim of this study is to describe the bacterial ecology and resistance profile of late VAP in a tertiary ICU in Morocco in order to adapt the empirical antibiotic therapy of late VAP and to prevent the emergence of MDRB.

Methods

This retrospective and descriptive study was conducted between April 2012 and April 2013 at the bacteriology laboratory of Mohammed V Military Instruction Hospital in Rabat. This hospital contains 700 beds capacity with a medical and a surgical care unit of 12 beds each. We included all pulmonary origin samples of intensive care units hospitalized patients who developed later VAP (occurring five days after ventilation [2,3]. VAP was defined according to CDC criteria [3]: a new and persistent infiltration present for more than 48 hours on a chest radiograph, plus two or more of the following: 1) fever of more than 38°C or less than 36°C; 2) leukocytosis of more than 10,000 or leucopenia of less than 5,000 cells/mL; 3) purulent tracheobronchial secretion; and 4) gas exchange degradation. Positive microbiological culture confirmation was also required [38].

Samples were collected by endotracheal aspiration (EA), bronchial aspiration (BA) and protected distal samples or broncho-alveolar washing. They were treated and interpreted according to REMIC recommendations [39], with a quantitative culture threshold of AET ≥ 10⁵ CFU/ml. The antibiotic sensitivity tests were performed and interpreted according to CA SFM [40]. Multidrug resistant bacteria included methicillin resistant *Staphylococcus aureus* (MRSA), *Enterobacteriaceae* producing extended-spectrum beta-lactamases (ESBLs) and/or hyper-produced cephalosporinases (HCP) and/or carbapenemase (Carb), non-fermenting negative gram bacilli resistant to third generation cephalosporins or imipenem [29,41]. The microbiological data extraction was performed using the expert system module (OSIRIS[®] software Biorad, French).

Results

During the study period, we collected 215 significant culture samples with 210 isolates; 112 (53.33%) from the medical intensive care unit and 98 (46.66%) from the surgical one. The Gram negative bacilli represented 81.42% of isolates while Gram positive cocci and Gram positive bacilli are less represented with a rate of 11.42% and 7.14% respectively. Non-lactose fermenting Gram negative bacilli made up the half of pathogens with 55.23% and the frequency of enteric bacilli was 26.19% of all isolates (Table 1).

Famille	Espec	Nombre N	Percentage (%)
BGN non Fermentant 116 (55.23%)	<i>Pseudomonas aeruginosa</i>	60	28.57
	<i>Acinetobacter baumannii</i>	52	24.76
	<i>Stenotrophomonas maltophilia</i>	3	1.42
	<i>Achromobacter xylosoxydans</i>	1	0.47
Enterobacteries 55 (26.19%)	<i>Klebsiella pneumonia</i>	17	8.09
	<i>Proteus spp</i>	11	5.23
	<i>Serratia sp</i>	11	5.23
	<i>Enterobacter sp</i>	7	3.33
	<i>E. Coli</i>	5	2.38
	<i>Providencia sp</i>	4	1.9
Coccia gram positif 24 (11.42%)	<i>Staphylococcus aureus</i>	20	9.52
	<i>Staphylococcus pneumoniae</i>	2	0.95
	<i>Staphylococcus CN</i>	1	0.47
	<i>Enterococcus faecalis</i>	1	0.47
Bacilles a gram positif 15 (7.14%)	<i>Corynebacterium striatum</i>	8	3.8
	<i>Corynebacterium sp</i>	7	3.33

Table 1: Distribution of bacteria species isolated (n=210).

Bacteria	Our study n=210	Erden et al. n=327	Kollef et al. n=499	Chastre et al. n=2490
<i>P. Aeruginosa</i>	28.60%	23.20%	21.20%	24.40%
<i>A.baumannii</i>	24.70%	37.00%	3.00%	7.90%
<i>K.pneumoniae</i>	8.10%	1.20%	8.40%	-
<i>S.aureus</i>	9.50%	27.80%	42.50%	20.40%
<i>Corynebacterium</i>	7.14%	-	22.90%	-

Table 2: Frequency of principal's species based on studies.




Figure 1: Resistance rates (R+I)* of *P. aeruginosa* isolates (n=60).




Figure 2: Resistance rates (R+I) of *A. baumannii* isolates (n=52).




Figure 3: Resistance rates (R+I) of *K. pneumonia* isolates (n=17).

Pseudomonas aeruginosa were the most isolates with the rate of 28.57%, followed by *Acinetobacter Baumannii* (24.76%), *Staphylococcus aureus* (9.52%) and *Klebsiella pneumonia* with the rate

of 8.09% (Table 2). The *corynebacteria* represented 7.14% of all isolates with a resistance rate of 7.10%.

Antimicrobial susceptibility profiles of *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* showed a high level of multidrug resistance up to 39.52% (Table 3) especially for *Acinetobacter baumannii*, *Pseudomonas aeruginosa* (Figures 1-3). They included imipenem-resistant *Pseudomonas aeruginosa* strains (14.28%), *Acinetobacter baumannii* carbapenem-resistant strains (19.04%) and ESBL and carbapenem-resistant *Klebsiella pneumonia* strains (5.71%). All *S. aureus* isolates were sensitive to methicillin and glycopeptides.

Species	ESBL(n)	OEC(n)	Carb(n)	Imper(n)	%MDR
<i>P.aeruginosa</i> (n=60)	0	4	3	23	14.28
<i>A. baumannii</i> (n=52)	0	1	40	0	19.52
<i>K. pneumoniae</i> (n=17)	6	0	6	0	5.71

MDR: Bacteria multiple drug resistance, ESBL: Extended-Spectrum Beta-lactamase,
OEC: overexpressed cephalosporinase, Carb: carbapenemase. Imper: impermeability.

Table 3: Betalactams Resistance profile of the main bacteria isolated.

Other species isolated were represented by *Proteus*, *Providencia* and *Serratia* that all accounted for 12.36% of all isolates and *Corynebacteria* with a rate of 7.14%.

Discussion

In our study, the late VAP bacterial epidemiology is dominated by Gram-negative bacilli with 81.42%. The Gram-negative, non-fermenting bacteria accounted for 67.83% and the enterobacteria for 32.16%. This dominance could be explained by the VAP physiopathology; lung contamination being due in one hand by modified endogenous flora of oropharynx and gastric fluid, mainly represented by enteric Gram-negative bacteria and *Pseudomonas aeruginosa* [42-44] and in the second hand, by exogenous flora from respiratory instruments or aerosols [3,42-45].

Pseudomonas aeruginosa, *Acinetobacter baumannii*, *Klebsiella pneumoniae* and *Staphylococcus aureus* are the predominating species. They are usually isolated in nosocomial infections, particularly in intensive care units [46]. However, the frequency of these species is very variable depending on regions, the structure and intensive care unit types [24,42,46,47].

The overall MDRB rate of late VAP in our study is very high (39.52%), but it is still inferior to that of other series namely in Greece [48] and in Brazil with a rates of 50% and 59% respectively [29]. The MDRB are represented first by Carbapenemase-producing *A. baumannii* isolates with the rate of 76.92% that remained only sensitive to polymyxin E, tobramycin and netilmicin (Figure 2). The imipenem *P. aeruginosa* resistance rate is 38.33% in our study with impermeability more prevailing than carbapenemases (Figure 1).

This resistance profile lead in most of case, to using polymixine E (colistine) as the only efficient drug given by parenteral route and by aerosol to the MDRB infections especially *Acinetobacter* and *Enterobacteriaceae* producing carbapenemases [49-52]. Therefore, we

recorded an increase incidence of bacterial species that are naturally resistant to polymyxin E (*Proteus*, *Providencia*, *Serratia* and *Corynebacteria* especially, multi-resistant one: *Corynebacterium striatum*). These results are in line with their reported increasing responsibility for VAP [46] and are a risk factor for inducing resistance to colistin in particular in case of its inadequate and inappropriate use as confirmed by other authors [49,50]. This resistance, non-noted in our region, appeared at the beginning of the century and is due to a modification of the lipid A of the bacterial plasma membrane and the presence of an efflux [53,54].

S. aureus accounted for only 9.52% of the isolates in our work, in contrast to other studies where it occupies the first place in Kollef et al. study [55] and the second place after *A. baumannii* in Erdem et al. one [56]. This low *S. aureus* rate is probably multifactorial including low nasal carriage in our context [57].

The frequency by species of ESBL *Klebsiella pneumoniae* isolates and carbapenemase *Klebsiella pneumoniae* isolates (35.29%) was higher than that found by some authors [29,41,58]. The emergence of these MDRB are attributable to multiple proven risk factors that include stay duration more than 5 days, recent antibiotic use, previous hospitalization, the frequency of these bacteria in intensive care units [46], and the empirical broad-spectrum antibiotics [29].

Conclusion

The late VAP is caused in most of cases, by BGN especially non-fermenting ones followed by Enterobacteria and in third rank gram positive bacteria. These species are most often multidrug resistant bacteria. This ecology indicates prescription of second line antimicrobial drug and especially colistine for *Acinetobacter baumannii* and *P. Aeruginosa* which expose to the emergence of naturally resistant species to this drug and some gram-positive bacteria. Hence, we recommend urgent implementation of efficient preventive actions, of note VAP bundles that had been proven to reduce the incidence of VAP.

Acknowledgement

The authors would like to thank technicians and all participants of bacteriological unit in the study for their cooperation during data collection by providing and/or facilitating collection of valuable information.

Financial support

None reported.

Ethics Approval and Consent to Participate

The study was approved by the ethic committee of faculty of Medicine and Pharmacy of Rabat, Morocco. In intensive care units, Patients families signed systematically a written consent for all the samples needed for intensive care and the possible use of the results (with respect of anonymity) for scientific purposes.

Consent to Publish

All the authors approve this paper publication in your journal.

Potential Conflicts of Interest

All authors report no conflicts of interest relevant to this article.

Authors Contributions

FM, LA, EM conceived of the Study conception and design: AN, MA participated in Data acquisition. FM, LA, MA performed analysis and interpretation of data. FM, LA: participated in drafting the manuscript. FM, EM had been involved in Critical revision of the manuscript for important intellectual content. AN performed statistical analysis. FM, LA, AN, MA and EM have given final approval of this version to be published.

References

1. Rosenthal VD, Maki DG, Jamultrat S, Medeiros EA, Todi SK, et al. (2010) International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. *Am J Infect Control* 38: 95-104.
2. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 171: 388-416.
3. Niederman MS, Craven DE (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 171: 388-416.
4. Vijai MN, Ravi PR, Setlur R, Vardhan H (2016) Efficacy of intermittent sub-glottic suctioning in prevention of ventilator-associated pneumonia-A preliminary study of 100 patients. *Indian J Anaesth* 60: 319-324.
5. Arabi Y, Al-Shirawi N, Memish Z, Anzueto A (2008) Ventilator-associated pneumonia in adults in developing countries: A systematic review. *Int J Infect Dis* 12: 505-512.
6. Madani N, Rosenthal VD, Dendane T, Abidi K, Zeggwagh AA, et al. (2009) Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: Findings of the International Nosocomial Infection Control Consortium (INICC). *Int Arch Med* 2: 29.
7. Lahsoune M, Boutayeb H, Zerouali K, Belabbes H, El mdaghri N (2007) Prévalence et état de sensibilité aux antibiotiques d'A. baumannii dans un CHU marocain. *Méd Mal Infect* 37: 828-831.
8. Razine R, Azzouzi A, Barkat A, Khoudri I, Hassouni F, et al. (2012) Prevalence of hospital-acquired infections in the university medical center of Rabat, Morocco. *Int Arch Med* 5: 26.
9. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, et al. (2008) Comprehensive evidence-based clinical practice guidelines for ventilator associated pneumonia: diagnosis and treatment. *J Crit Care* 23: 138-147.
10. Chastre J, Fagon JY (2003) Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 165: 867-903.
11. Berenholtz SM, Pharm JC, Thompson DA, Nadham DM, Lubomski LH, et al. (2011) Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. *Infect Control Hosp Epidemiol* 32: 305-314.
12. Andrews T, Steen C (2013) A review of oral preventative strategies to reduce ventilator-associated pneumonia. *Nurs Crit Care* 18: 116-122.
13. Bouza E, Burillo A (2009) Advances in the prevention and management of ventilator-associated pneumonia. *Curr Opin Infect Dis* 22: 345-351.
14. Vincent JL, Sakar Y, Sprung CL, Ranier VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of SOAP study. *Crit Care Med* 34: 344-353.
15. Chawla R (2008) Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. *Am J Infect Control* 36: S93-S100.
16. Arabi Y, Haddad S, Hawes R, Moore T, Pillay M, et al. (2007) Changing sedation practices in the intensive care unit: protocol implementation,

- multifaceted multidisciplinary approach and teamwork. *Middle East J Anesthesiol* 19: 429-447.
17. <http://www.ihl.org/IHI/Programs/Campaign/100kLivesCampaignSuccessStories.htm>
 18. <http://www.ihl.org/IHI/Programs/Campaign/Campaign.htm?TabId=1>
 19. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, et al. (2005) Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. *Jt Comm J Qual Patient Saf* 31: 243-248.
 20. Al-Tawfiq JA, Abed MS (2010) Decreasing ventilator-associated pneumonia in adult intensive care units using the Institute for Healthcare Improvement bundle. *Am J Infect Control* 38: 552-556.
 21. Unahalekhaka A, Jamulitrat S, Chongsuvivatwong V, Ovretveit J (2007) Using a collaborative to reduce ventilator-associated pneumonia in Thailand. *Jt Comm J Qual Patient Saf* 33: 387-394.
 22. Bonello RS, Fletcher CE, Becker WK, Clutter KL, Arjes SL, et al. (2008) An intensive care unit quality improvement collaborative in nine Department of Veterans Affairs hospitals: reducing ventilator-associated pneumonia and catheter-related bloodstream infection rates. *Jt Comm J Qual Patient Saf* 34: 639-645.
 23. Hawe CS, Ellis KS, Cairns CJ, Longmate A (2009) Reduction of ventilator associated pneumonia: active versus passive guideline implementation. *Intensive Care Med* 35: 1180-1186.
 24. Legras A, Malvy D, Quinioux AL, Villiers D, Bouachour G, et al. (1998) Nosocomial infections: prospective survey of incidence in five french intensive care units. *Intensive Care Med* 24: 1040-1046.
 25. Woske HJ, Röding T, Schulz I, Lode H (2001) Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. *Crit Care* 5: 167-173.
 26. Bouza E, Perez A, Munoz P, Jesus Perez M, Rincon C, et al. (2003) Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. *Crit Care Med* 31: 1964-1970.
 27. Urli T, Perone G, Acquarolo A, Zappa S, Antonini B, et al. (2002) Surveillance of infections acquired in intensive care: usefulness in clinical practice. *J Hosp Infect* 52: 130-135.
 28. Resende M M, Monteiro S G, Callegari B, Figueiredo P M S, Monteiro C R A V, et al. (2013) Epidemiology and outcomes of ventilator-associated pneumonia in northern Brazil: an analytical descriptive prospective cohort study. *BMC Infect Dis* 13: 119.
 29. Camargo LF, De Marco FV, Barbas CS, Hoelz C, Bueno MA, et al. (2004) Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates. *Crit Care* 8: R422-R430.
 30. Kanafani ZA, Kara L, Hayek S, Kanj SS (2003) Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms. *Infect Control Hosp Epidemiol* 24: 864-869.
 31. Thongpiyapoom S, Narong MN, Suwalak N, Jamulitrat S, Intaraksa P, et al. (2004) Device-associated infections and patterns of antimicrobial resistance in a medical-surgical intensive care unit in a university hospital in Thailand. *J Med Assoc Thai* 87: 819-824.
 32. Ertugrul BM, Yildirim A, Ay P, Oncu S, Cagatay A, et al. (2006) Ventilator-associated pneumonia in surgical emergency intensive care unit. *Saudi Med J* 27: 52-57.
 33. Luna CM, Aruj P, Niederman MS, Garzon J, Violi D, et al. (2006) Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. *Eur Respir J* 27: 158-164.
 34. Wu CL, Yang D, Wang NY, Kuo HT, Chen PZ (2002) Quantitative culture of endotracheal aspirates in the diagnosis of ventilator-associated pneumonia in patients with treatment failure. *Chest* 122: 662-668.
 35. Amor M, Talha Y, Maazouzi W (2014) Facteurs de risque de pneumopathie acquise sous ventilation mécanique (PAVM) chez les patients cérébrolésés. *Réanimation* 24: S118-S122.
 36. Shimi A, Touzani S, Elbakouri N, Bechri B, Derkaoui A, et al. (2015) Pneumopathies nosocomiales en réanimation de CHU Hassan II de Fès. *Pan African Medical Journal* 22: 285.
 37. Kollef MH, Silver P, Murphy DM, Trovillion E (1995) The effect of late-onset ventilator-associated pneumonia in determining patient mortality. *Chest* 108: 1655-1662.
 38. Repository of medical microbiology (Remic) (2010) Microbiological diagnosis of bronchopulmonary infections, 4th edition 2010 Chapter 13: 93-98.
 39. Soussy JC (2014) Antibigram committee of the French society of Microbiology.
 40. Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, et al. (2008) Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. *Crit Care* 12: R142.
 41. Joseph N M (2010) Ventilator-associated pneumonia: A review. *Euro j of int med* 21: 360-368.
 42. Niederman MS, Craven DE (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 171: 388-416.
 43. Safdar N, Crnich CJ, Maki DG (2005) The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. *Respir Care* 50: 725-739.
 44. Ewig S, Torres A, El-Ebiary M, (1999) Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator associated pneumonia. *Am J Respir Crit Care Med* 159: 188-98.
 45. Torres A, El-Ebiary M, Soler N, Monton C, Fabregas N, et al. (1996) Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. *Eur Respir J* 9: 1729-1735.
 46. Park DR (2005) The microbiology of ventilator-associated pneumonia. *Respir Care* 50: 742-763.
 47. Niederman MS (2001) Cost effectiveness in treating ventilator-associated pneumonia. *Am J Respir Crit Care Med* 5: 243-244.
 48. Wertheim H, Kinh Van Nguyen, Gabriel Levy Hara, Hellen Gelband, Ramanan Laxminarayan, et al. (2013) Global survey of polymyxin use: a call for international guidelines. *J of Global Antimicrobial Resistance* 1: 131-134.
 49. Salomon J (2011) Pansusceptible *Proteus mirabilis* septicemia in a patient multicolonized by pan-resistant bacteria. *Med mal infect* 41: 262-263.
 50. Hayakawa K, Marchaim D, Divine G W, Pogue J M., Kumar S, et al. (2012) Growing prevalence of *Providencia stuartii* associated with the increased usage of colistin at a tertiary health care center International. *J Infect Dis* 16: 646-648.
 51. Hays C, Benouda A, Poirel L, Elouennass M, Nordmann P et al. (2012) Nosocomial occurrence of OXA-48-producing enterobacterial isolates in a Moroccan hospital. *Int. J Antimicrob Agents* 39: 545-547.
 52. Rios FG, Luna CM, Maskin B, Saenz Valiente A, (2007) Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. *Eur Respir J* 30: 307-313.
 53. Mezghani Maalej S, Rekik Meziou M, Mahjoubi F, Hammami A (2012) Epidemiological study of Enterobacteriaceae resistance to colistin in Sfax. *Méd Mal Inf* 42: 256-263.
 54. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, et al. (2010) Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 beta-lactamase resistant to colistin. *J Hosp Infect.* 76: 70-73.
 55. Kollef MH, Morrow LE, Niederman MS, Leeper KV, Anzueto A, et al. (2006) Clinical characteristic and treatment patterns among patients with ventilator-associated pneumonia. *Chest* 129: 1210-1218.
 56. Erdem I, Ozgultekin A, Inan AS, Dincer E, Turan G, et al. (2008) Incidence, etiology, and antibiotic resistance patterns of gram-negative microorganisms isolated from patients with ventilator-associated pneumonia in a medical-surgical intensive care unit of a teaching hospital in Istanbul, Turkey (2004-2006). *Jpn J Infect Dis* 61: 339-342.

-
57. Oztoprak N, Cevik MA, Akinci E, Korkmaz M, Erbay A, et al. (2006) Risk factors for ICU-acquired methicillin-resistant *Staphylococcus aureus* infections. *Am J Infect Control* 34: 1-5.
58. Guimares MM, Rocco JR (2006) Prevalence of ventilator-associated pneumonia in a university hospital and prognosis for the patients affected. *J Bras Pneumol* 32: 339-346.